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Evaluation of the Role of Shiga and Shiga-like Toxins in Mediating 
Direct Damage to Human Vascular Endothelial Cells 
Vernon L. Tesh, James E. Samuel,* Liyanage P. Perera, 
John B. Sharefkin, and Alison D. O'Brien 
Departments of Microbiology and Surgery, Uniformed Services University 
of the Health Sciences, Bethesda, Maryland 
Infection with Shiga toxin- and Shiga-like toxin-producing strains of Shigella dysenteriae and 
Escherichia colif respectively, can progress to the hemolytic-uremic syndrome. It has been hy- 
pothesized that circulating Shiga toxin, Shiga-like toxins, and endotoxins may contribute to the 
disease by directly damaging glomerular endothelial cells. The effects of these toxins on HeLa, 
Vero, and human vascular endothelial cells (EC) were examined. Confluent EC were sensitive to 
Shiga toxin but were at least 106 -fold less sensitive to the toxins than were Vero cells. Shiga toxin 
was the predominant cytotoxic factor. Lipopolysaccharides were not cytotoxic and did not aug- 
ment Shiga toxin-mediated toxicity. Lower doses of Shiga toxin caused cytotoxicity when coin- 
cubated with tumor necrosis factor. The relative resistance of EC to Shiga toxin and Shiga-like 
toxins may be due to reduced toxin binding, as low levels of globotriaosylceramide (Gb3), the 
toxin-specific receptor, were found in EC membranes. 
Inflammatory bacterial colitis caused by infection with 
Shigella species continues to be a major cause of morbidity 
and mortality in underdeveloped countries, especially 
among young children [1]. Of particular interest is Shigella 
dysenteriae type 1, which is capable of causing epidemic out- 
breaks of dysentery. In addition, it has recently been shown 
that some strains of Escherichia coli, particularly E. coli sero- 
type 0157:H7, can cause hemorrhagic colitis [2, 3]. Collec- 
tively, these E. coli strains are referred to as enterohemor- 
rhagic E. coli (EHEC). S. dysenteriae type 1 and EHEC share 
the characteristic of producing high levels of protein toxins 
called Shiga toxin or Shiga-like toxins (SLTs or Verotoxins), 
respectively. EHEC may produce two antigenically distinct 
toxins, designated SLT-I and SLT-II. SLT-I is essentially 
identical to Shiga toxin, and its cytotoxic activity for Vero or 
HeLa cells can be neutralized with anti-Shiga antibodies [4, 
5]. SLT-II is 567c homologous to Shiga toxin/SLT-I at the 
deduced amino acid level, and its cytotoxicity is not blocked 
by anti-Shiga toxin antibodies [5, 6]. 
Shiga toxin and SLTs are holotoxins that consist of a sin- 
gle 32- to 33-kDa A subunit in association with a pentamer 
of 7.7-kDa B subunits [7]. The A subunit is a specific N-gly- 
cosidase that selectively cleaves a single adenine residue 
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from the 28S rRNA component of the 60S eukaryotic ribo- 
some complex [8, 9]. The B subunit mediates binding of the 
holotoxin to specific glycolipid receptors in mammalian cell 
membranes [10-13]. Although the precise role of Shiga 
toxin and the SLTs in the pathogenesis of bacillary dysentery 
and hemorrhagic colitis, respectively, is not fully under- 
stood, there is now convincing evidence to suggest that the 
toxins are important virulence factors in the development of 
bloody, edematous vascular lesions of the colon [14]. The 
toxins may also participate in the direct killing of colonic 
epithelial cells and may provoke fluid secretion and diarrhea 
in the host [7]. 
Perhaps the most serious sequela of colitis caused by S. 
dysenteriae type 1 or EHEC is the progression of the disease 
to the hemolytic-uremic syndrome (HUS), which is charac- 
terized by acute renal failure, thrombotic microangiopathy, 
and thrombocytopenia [15]. Histopathologic studies of the 
kidneys of HUS patients have shown profound alterations in 
the glomeruli. More specifically, glomerular endothelial cells 
(EC) appear swollen, and there is abundant fibrin deposition 
and inflammatory cell influx in the lumina of the glomeruli 
[16]. These observations, as well as the critical role of EC in 
maintaining normal blood flow [ 17], have led to the concept 
that systemic Shiga toxin or SLTs may specifically target the 
glomerular EC for damage and thereby contribute to the de- 
velopment of HUS. In support of this hypothesis, Obrig et al. 
[18] showed that Shiga toxin preparations are cytotoxic for 
human umbilical vein EC (HUVEC) in vitro. 
In the experiments reported here, we assessed the cyto- 
toxic potential of crude Shiga toxin, SLT-II, and affinity-pu- 
rified Shiga toxin for confluent human saphenous vein EC 
(HSVEC) and HUVEC monolayers. In addition, we com- 
pared Shiga toxin-mediated EC and Vero cell cytotoxicity 
and examined the role of lipopolysaccharides (LPS) and re- 
combinant human tumor necrosis factor-a in direct EC cyto- 
JID 1991; 164 (August) Shiga Toxin and SLT-II-Mediated EC Toxicity 345 
toxicity. Finally, we analyzed toxin binding to intact EC and 
quantitated levels of toxin receptor in EC membranes. 
Materials and Methods 
Bacterial strains and plasmids. S. dysenteriae type 1 strain 
3818T produces high levels of Shiga toxin and was isolated from 
a patient with severe dysentery in Central America [19]. E. coli 
0157:H7 strain 933 produces both SLT-I and II and was iso- 
lated from an outbreak of hemorrhagic colitis in the United 
States [2, 5]. Toxins used in this study were derived from E. coli 
DH5a (Bethesda Research Laboratories, Gaithersburg, MD) 
transformed with recombinant plasmids containing the cloned 
toxin genes. E. coli (pLPSH3) harbors the plasmid pBR328 that 
contains the entire Shiga toxin operon on a 5.9-kb Bglll-Sall 
insert subcloned from pNAS 10 [4,20]. E. coli (pLP32) harbors a 
Bluescribe vector (pBS[?] phagemid kit; Stratagene, La Jolla, 
CA) with a 3.0-kb Sphl-Kpnl fragment from pNN76 encoding 
SLT-II [21, 22]. Clones producing high levels of toxin were 
maintained under BL3 -f- EK1 containment [23]. 
Toxin preparations. LPS were prepared from S. dysenteriae 
3818T and E. coli 933 by the hot aqueous-phenol method of 
Westphal and Jann [24]. The pooled aqueous phases were dia- 
lyzed against nine changes of double-distilled, deionized HjO, 
concentrated 10-fold (Amicon, Danvers, MA), and lyophilized. 
LPS preparations contained ^ Mg/ml protein (BCA protein as- 
say; Pierce Chemical, Rockford, IL). E. coli Ol 11:B4 LPS was 
purchased from Sigma Chemical (St. Louis). Concentrated 
crude Shiga toxin and SLT-II were prepared from E. coli 
(pLPSH3) and E. coli (pLP32), respectively. The strains were 
grown at 370C in 50 ml of Luria broth (LB) containing 250 
Mg/ml ampicillin for 24 or 48 h with constant agitation. The 
bacteria were pelleted by centrifugation, washed, and resus- 
pended in 5.0 ml of LB. The bacteria were disrupted by sonica- 
tion and the lysates cleared by centrifugation at 12,000 g for 15 
min. Toxins in the clarified lysates were concentrated by precipi- 
tation with 60(3d saturated ammonium sulfate. The precipitates 
were resuspended in 5.0 ml of PBS and dialyzed overnight 
against PBS. Toxins prepared in this manner reproducibly con- 
tained ~ 108 -109 CDso/ml when assessed by the Vero cell cyto- 
toxicity assay. Purified Shiga toxin was prepared from this crude 
starting material as described [22, 25]. Briefly, crude toxin was 
passed over a DEAE-Sepharose column equilibrated with 0.05 
M TRIS buffer and eluted with a gradient of 0-1.0 M NaCl in 
0.05 M TRIS buffer. Fractions cytotoxic for Vero cells were 
pooled and passed over a chromatofocusing column. Cytotoxic 
fractions were pooled, dialyzed, and passed over an antitoxin 
affinity column. Shiga toxin was eluted with 0.05 M glycine, 
dialyzed against PBS, and stored at 40C until used. Purified 
Shiga toxin preparations contained k0. 1 ng/ml endotoxin as 
assessed by limulus amoebocyte lysate gelation (Endotect; 
Schwarz/Mann Biotech, Cleveland). 
Recombinant human tumor necrosis factor-a (rhTNFa). 
rhTNFa (lot NBP-802A; 2.7 X 107 units/mg) was the gift of A. 
Creasey (Cetus, Emeryville, CA). Before use in cytotoxicity as- 
says, the lyophilized cytokine was resuspended to 260 pg/ml in 
sterile pyrogen-free water (Travenol Laboratories, Deerfield, 
IL). The stock preparations were then diluted in growth medium 
as needed. 
Tissue culture. Vero and HeLa cells were maintained in Ea- 
gle's MEM (Flow Laboratories, McLean, VA) supplemented 
with \07c fetal bovine serum, 10 mM L-glutamine, 50 units/ml 
penicillin, and 50 Mg/ml streptomycin. EC were harvested from 
adult human saphenous veins (HSV) obtained during coronary 
bypass operations as previously described [26]. Vein segments 
(~2.5 cm) were transported to the laboratory in chilled blood 
with 100 units/ml preservative-free heparin (Sigma). The HSV 
were cannulated and flushed with cold Ca"^ - and Mg^ -free 
Dulbecco's PBS (PBS-CMF; GIBCO, Grand Island, NY). HSV 
were ligated after filling to slight distension with 0.17c CLS II 
collagenase (Worthington Diagnostic Systems, Freehold, NJ) 
and 0.5^ bovine serum albumin (BSA) in PBS-CMF and im- 
mersed in Hanks' balanced salt solution (GIBCO) for 15 min at 
370C. HSV were flushed with 10 ml of cold complete medium 
(CM) composed of Medium 199 (GIBCO) with 207c fetal bovine 
serum (Hyclone Laboratories, Logan, UT), 100 pg/ml heparin 
(Sigma), 100 pg/ml L-glutamine, 50 units/ml penicillin, 50 pg/ 
ml streptomycin (GIBCO), and 2 pg/ml amphotericin B (Fungi- 
zone; GIBCO). 
The vein contents were centrifuged (200 g, 1 min, 40C), and 
the cell pellet was resuspended in 1.0 ml of CM supplemented 
with 20 /d/ml EC-mitogen extract prepared from bovine retina 
using a modification of a previously described method [27, 28]. 
The cells were placed in single wells of 24-well plates (Falcon; 
Becton Dickinson Labware, Oxnard, CA) coated with 1 pg/cm2 
human fibronectin and incubated at 370C in humidified 57c 
C02. The other wells were filled with sterile PBS-CMF to mini- 
mize changes in osmolality. Cells were fed every other day with 
fresh CM containing 10 pl/ml bovine retinal extract (CM-BRE). 
When primary cultures became confluent, HSVEC were de- 
tached using 0.05% trypsin-0.02% EDTA, washed in CM with 
107c serum, and resuspended in CM-BRE. Subsequent passages 
of HSVEC were plated on gelatin-coated 25-cm2 tissue culture 
flasks or 96-well microtiter plates. All experiments were done 
with HSVEC passaged two to five times in vitro. 
HSVEC were characterized by inverted-phase microscopic 
observation of cell morphology and immunoenzymatic staining 
for factor VHI-related antigen (Endo-RAP I.D.; Endotech, In- 
dianapolis). Primary HUVEC were the gift of D. Silverman (De- 
partment of Microbiology, University of Maryland School of 
Medicine, Baltimore). HUVEC were passaged and maintained 
as described above. 
Cytotoxicity assays. The cytotoxicity of toxin preparations 
for Vero cells was determined as described [29]. Vero cells were 
plated at ~ 104 cells/well in 96-well plates and incubated over- 
night at 370C in 57c CO2. Toxin preparations were serially di- 
luted in complete Eagle's MEM medium, and 100 pi of the 
dilutions was transferred to the cells. Incubation was continued 
for 48 h. The cells were fixed with formalin and stained with 
0.137c crystal violet. Absorbance was measured at 620 nm. A 
50% cytotoxic dose (CD5o) represents the reciprocal dilution of 
toxin necessary to kill 50^ of the Vero cells in a well. The cyto- 
toxic potency of toxin preparations is defined as the number of 
CD50 per milliliter of toxin preparation. Cytotoxicity of toxin 
preparations for EC was assessed by hemocytometer counts or 
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by spectrophotometry. EC were plated on the interior 24 wells 
of gelatin-coated 96-well plates at ~2 X 104 cells per well. Exte- 
rior wells were filled with PBS-CMF. When the cells reached 
confluence, fresh CM-BRE containing the toxin(s) to be assayed 
were added to triplicate wells in a total volume of 200 pi. Incu- 
bation was continued at 370C in 57c C02. Cells that subse- 
quently detached from the gelatin substratum failed to exclude 
trypan blue, or after extensive washing, did not grow when re- 
cultured on gelatin-coated plates. 
Viable cells were stained for counting in a hemocytometer by 
replacing the growth medium with 60 pi of 0.17c crystal violet in 
0.1 M citric acid (pH 7.26). After the cells were incubated with 
the dye at 370C for 20 min, the wells were scraped with sterile 
pipette tips, and 15 /d of cell suspension was transferred to the 
hemocytometer. Stained nuclei were then counted. Cells were 
counted using a microtiter plate reader according to the method 
of Brasaemle and Attie [30]. Cells were washed with warm PBS- 
CMF, and 100 pi of methanol per well was added for 15 min at 
room temperature. The methanol was aspirated from the wells, 
the plates were air dried, and 100 pi of 0.17c crystal violet was 
added to each well for 5 min. After the dye was removed and the 
plates dried, each well was washed with HjO, and the stained 
cells were solubilized with 100 pi of 27c (wt/vol) sodium deoxy- 
cholate. The plates were heated in a microwave oven (Samsung 
MW5510; setting 2) for 1 min, and agitated (mini-orbital 
shaker, setting 6; Bellco Glass, Vineland, NJ) for 10 min. Absor- 
bance was read at 570 nm. Cell counts were correlated by linear 
regression analysis of hemocytometer cgunts of stained nuclei 
against absorbance measurements of triplicate serial twofold di- 
lutions of EC. This assay produced a linear standard curve be- 
tween 1.5 X 103 and 6 X 104 cells per well (mean R value, .92). 
Data were expressed as percentage of viability, which is defined 
as (number of cells H- toxin ? background/number of control 
cells ? background) X 100. Background absorbance was de- 
rived from staining blank wells. Control cells were incubated 
with CM-BRE only. 
Neutralization assay. Dilutions of toxins were made in ap- 
propriate growth media in 96-well plates (100 pl/well), and 100 
pi of anti-Shiga toxin monoclonal antibody (MAb 13C4) was 
added to each well. The plates were agitated, incubated at 370C 
in 57c CO2 for 1 h, and kept overnight at 40C. Toxin-antitoxin 
mixtures (100 pi) were then added to Vero cells or EC, and 
cytotoxicity was determined as described above. An isotype- 
matched MAb directed against the B subunit of cholera toxin 
[31] did not affect cytotoxicity in this assay. 
Analysis of toxin binding to whole cells. A modification of an 
immunofluorescence protocol using a computer-assisted scan- 
ning laser instrument (ACAS 470; Meridian Instruments, Oke- 
mos, MI) was devised to compare Shiga toxin binding to EC 
versus Vero and HeLa cells [20, 32]. Cells were trypsinized and 
adjusted to ~5 X 105 cells/ml in cold diluent buffer (phenol 
red-free Earle's balanced salt solution [EBSS; GIBCO] contain- 
ing 10^. fetal bovine serum and 0.1^ Na^). Concentrated 
crude Shiga toxin (50 pi; ~ 109 Vero cell CD507ml) was added to 
450 pi of cells in Eppendorf tubes and agitated at 40C for 60 
min. Unless otherwise noted, all binding and washing steps were 
done at 40C. Unbound toxin was removed by three washes with 
cold diluent buffer. 
The cells were resuspended in 500 pi of a 1:100 dilution of 
primary antibody and agitated for 45 min. Primary antibodies 
used were 4F7, monoclonal IgG 1 directed against the A subunit 
of Shiga toxin [33]; 13C4, monoclonal IgG 1 directed against the 
B subunit of Shiga toxin [34]; and BC5BB12, monoclonal IgGl 
directed against the B subunit of SLT-II [35]. Unbound anti- 
body was removed by three washes with diluent buffer, and sec- 
ondary antibody (500 pi of a 1:100 dilution of a fluorescein 
isothiocyanate-conjugated goat F[ab']2 anti-mouse IgG; Cappel 
Laboratories, Westchester, PA) was added to the cells. After 
unbound secondary antibody was washed out, the cells were 
treated with 100 pi of a fluorescent nonspecific membrane 
probe, l,r-dioctadecyl-3,3,3' ,3' -tetramethyl indocarbocyanine 
perchlorate (5 pg/ml in 17c ethanol and serum-free EBSS; Molec- 
ular Probes, Eugene, OR) at 370C for 10 min. 
After extensive washing with cold serum-free EBSS, the cells 
were transferred to flat-bottomed 96-well plates and centrifuged 
for 10 min (200 g) at 40C. The plates were immediately scanned 
using the Meridian ACAS 470 equipped with a 5-W argon laser 
tuned to 488 nm. Laser power was adjusted to 200 mW and scan 
strength adjusted to 357c. The collimated first-order beam was 
directed through a standard dichroic filter cube. (See [32] for a 
more detailed description of laser parameters.) Qualitative analy- 
sis of Shiga toxin binding was done by microcomputer conver- 
sion of fluorescent emissions into a 15-pseudocolor scan based 
on fluorescence intensity. 
Thin-layer chromatography of toxin-binding glycolipids. To- 
tal lipid extracts from HSVEC, HUVEC, Vero, and HeLa cells 
were subjected to chromatography on aluminum-backed silica 
gel thin-layer chromatography plates (silica gel 60; Merck AG, 
Darmstadt, FRG) with CHCl3-CH3OH-0.257o aqueous KC1 
(5:4:1) as previously described [22, 36]. Purified glycolipids 
served as controls. After chromatography, the chromatography 
plates were coated with 0.17c polyisobutylmethacrylate (Poly- 
science, Warrington, PA), air dried, and sprayed with TBS-BSA 
(0.1 M TRIS-HC1 [pH 7.4], 0.15 M NaCl, 17c BSA). The plates 
were overlaid with ~105 CD507ml Shiga toxin in TBS-BSA. 
After incubation at 40C, the plates were extensively washed 
with PBS and overlaid with MAb 13C4 diluted in TBS-BSA. 
Goat anti-mouse IgG labeled with 125I was used as secondary 
antibody. The plates were washed, air dried, and specific bind- 
ing was visualized by autoradiography. Relative amounts of 
toxin-binding glycolipids were estimated from peak areas of den- 
sitometric scans obtained with a densitometer (CS9000U; Shi- 
madzu, Kyoto, Japan) and compared with serial dilutions of the 
control glycolipid globotriaosylceramide (Gb3). Autoradio- 
graphs of several exposure times for each thin layer chromatogra- 
phy plate were scanned to ensure the peak areas were within the 
linear range of the densitometer. 
Statistical analysis. The significance of differences between 
means of samples was determined by Student's two-tailed t test. 
P < .025 was considered significant. 
Results 
Role of Shiga toxin, SLT-II, and LPS in direct EC cytotoxic- 
ity. To assess the cytotoxic potential of Shiga toxin for 
HSVEC, various dilutions of crude Shiga toxin preparations 
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Figure 1. Effect of crude and purified Shiga toxin on endothelial 
cell viability. Confluent human saphenous vein endothelial cell 
(HSVEC) monolayers were incubated with dilutions of (A) crude 
or (B) affinity-purified Shiga toxin. At the indicated time points, 
the numbers of viable, adherent cells were determined and com- 
pared to HSVEC cultured in the absence of toxin. Toxin dilutions 
were made on the basis of Vero cell 50^ cytotoxic doses (CD50): 
S, 109; A, 107; I, 105; T, 103 (all CD5o). Error bars indicate SD. 
were incubated with confluent EC monolayers, and the num- 
ber of viable cells remaining attached to gelatin-coated wells 
was determined by hemocytometer counting or spectropho- 
tometry. The incubation of HSVEC with the highest dilu- 
tions of crude Shiga toxin resulted in a dose-dependent kill- 
ing of the cells (figure 1 A). Cytotoxicity occurred within the 
first 24 h of incubation, and EC viability remained reduced 
relative to control cells over 72 h. When HUVEC were used 
as target cells, the kinetics and dose response of Shiga toxin- 
mediated toxicity were essentially identical to those of 
HSVEC (data not shown). Treatment of both EC types with 
crude SLT-II preparations killed the cells in a manner similar 
to crude Shiga toxin (data not shown). Finally, treatment of 
both EC types with affinity-purified Shiga toxin resulted in 
killing that was similar to that observed with crude toxin 
preparations (figure 1B). Dilutions of the toxins were made 
based on cytotoxicity for Vero cells. From these data, we 
estimated that 1 EC CD50 was roughly equivalent to 107 
Vero cell CD50, or ~ 1.4 X 10~8 M Shiga toxin. These results 
suggest, therefore, that while confluent human EC derived 
from large veins are sensitive to Shiga toxin, they are at least 
106 -fold less susceptible than Vero cells. 
The observation that purified Shiga toxin killed EC in a 
manner similar to crude toxin preparations suggested that 
Shiga toxin was the primary mediator of cytotoxicity for EC. 
However, the effects of small amounts of endotoxin present 
in the toxin preparations could not be discounted, especially 
in light of recent evidence that nanogram quantities of endo- 
toxins can have profound effects on EC function [37-39]. 
To more fully assess the role of Shiga toxin in EC cytotoxic- 
ity, we incubated the cells with varying amounts of affinity- 
purified Shiga toxin in the presence or absence of anti-Shiga 
toxin MAb (table 1). Even at the highest toxin concentration 
tested, cytotoxicity was completely neutralized by antitoxin 
antibody. Antibody alone had no effect on cell viability, and 
the addition of an irrelevant, isotype-matched MAb did not 
block Shiga toxin cell killing (data not shown). The observa- 
tion that MAb directed against Shiga toxin neutralizes cyto- 
toxicity provides further evidence in support of the concept 
that, in vitro, Shiga toxin is the predominant mediator of 
direct EC cytotoxicity. 
In light of clinical evidence suggesting that patients with 
HUS are frequently endotoxemic [40] as well as histopatho- 
Table 1. Neutralization of endothelial cell (EC) cytotoxicity with 
anti-Shiga toxin monoclonal antibody (MAb). 
Duration of EC exposure to toxin 
24 h 72 h 
Toxin dose 
in CD50Zml* No. MAb With MAb No. MAb With MAb 
109 42.2 ?17.3 104.6 ?3.2 20.0 ? 5.0 96.7 ? 8.6 
107 52.7 ?6.0 100.4 ?6.5 50.1 ?4.9 110.0 ?2.3 
105 91.6 ?4.9 109.1 ?3.2 100.1 ?8.8 106.6 ?3.0 
NOTE. Confluent EC were incubated for 24 or 72 h with the indicated doses 
of Shiga toxin, in the presence or absence of anti-Shiga toxin MAb. The number of 
substratum-adherent cells was determined as described in Materials and Methods. 
Data are percentages of viable EC ? SD. 
* Number of Vero cell CD50fm\. 
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Figure 2. Effect of Shiga toxin (ShT) versus lipopolysaccharides 
(LPS) on endothelial cell (EC) viability that was determined after 
confluent cells were incubated 48 h with ~ 1 EC 50% cytotoxic 
dose (1 EC CD50 ^  107 Vero cell CD5o) of purified ShT only; 10 
Mg/ml LPS derived from Escherichia coli 0111 :B4, E. coli 0157:H7 
strain 933, or Shigella dysenteriae 3818T; or mixtures of 1 EC CD50 
ShT and LPS. Error bars = SD. Differences between samples were 
analyzed by Student's two-tailed t test; P < .025 was significant. 
logic data suggesting that endotoxins may contribute to the 
pathologic changes in the kidney characteristic of HUS [41], 
we queried whether LPS might play a direct role on in vitro 
EC killing. We demonstrated that purified LPS derived from 
S. dysenteriae type 1 and EHEC strains were not directly 
cytotoxic for confluent human EC monolayers (figure 2) or 
Vero cells (data not shown) at doses as high as 10 pgjml. 
Furthermore, the coincubation of EC with 10-fold dilutions 
of LPS and a constant dose of affinity-purified Shiga toxin 
(~1 EC CD50) did not have a statistically significant effect 
on EC cytotoxicity in comparison with treatment with Shiga 
toxin alone (P ^ .025). Thus, while the presence of endotox- 
ins in vivo may be an important factor in the pathogenesis of 
HUS, purified LPS alone does not appear to be a major deter- 
minant of direct EC cytotoxicity in vitro. 
LPS elicits the synthesis and secretion of TNFa by mono- 
cytes and macrophages. TNFa may have pleiotropic effects 
in vivo, and this cytokine has emerged as a central mediator 
in initiating and regulating the complex cascade of events 
that results in a procoagulant and proinflammatory state in 
the vasculature [42]. However, the contributory effect, if 
any, of TNFa in Shiga toxin-mediated direct EC cytotoxic- 
ity is not clear. We therefore coincubated EC with dilutions 
of Shiga toxin and rhTNFa and assessed EC cytotoxicity. In 
the presence of 10 ng/ml rhTNFa, we detected an ~ 100- 
fold reduction in the Shiga toxin EC CD50 (table 2). 
Comparative analysis of Shiga toxin and SLT-II binding to 
intact cells. Shiga toxin and SLTs bind to specific glycolipid 
receptors in the membranes of Vero or HeLa cells [10-13]. 
Antibody neutralization, competitive binding, and holo- 
toxin dissolution studies have shown binding to be an essen- 
tial step in target cell intoxication and death [5, 43, 44]. 
Therefore, reduced binding of Shiga toxin and SLT-II to EC 
is one possible mechanism to explain the relative insensitiv- 
ity of EC to the toxins. 
To assess toxin binding to intact EC and to compare bind- 
ing to control cells, we devised an indirect immunofluores- 
cence assay using a computer-assisted laser scanner that con- 
verted fluorescence intensity into a pseudocolor spectrum. 
To monitor toxin binding, EC, Vero, and HeLa cells were 
treated with equivalent doses of Shiga toxin or SLT-II in 
suspension, and toxin binding was detected with antitoxin 
antibodies and fluorescein isothiocyanate-conjugated sec- 
ondary antibody. The cells were then treated with a nonspe- 
cific, fluorescent membrane intercalator to outline the cells 
and allow comparison of levels of toxin-specific fluorescence 
within the same field. As shown in figure 3A, in any given 
field, virtually every Vero (left panel) or HeLa cell (right 
panel) was intensely stained after treatment with Shiga toxin. 
Although every cell showed toxin-specific fluorescence, the 
intensity varied between cells (i.e., not every cell appeared to 
bind toxin equivalently). The fluorescence intensity and 
binding pattern of SLT-II for Vero cells was similar to that 
seen with Shiga toxin (data not shown). Since essentially 
every cell bound Shiga toxin, the binding pattern produced 
by the nonspecific membrane probe was nearly identical to 
toxin-specific fluorescence (not shown). In contrast to Vero 
or HeLa cells, when EC were treated with an equivalent dose 
of Shiga toxin or SLT-II, much lower levels of fluorescence 
were detected (figure 3B, C, left panels), indicating reduced 
toxin binding in comparison to Vero and HeLa cells. As with 
the control cells, however, there appeared to be differences 
in the amounts of toxin bound to each individual EC. Some 
cells showed very low levels of fluorescence; others showed a 
more intense, punctate binding pattern. These data suggest 
that if toxin binding and cell killing are directly correlated, 
then EC may be heterogeneous in terms of sensitivity to 
Shiga toxin. Use of the fluorescent membrane probe (figure 
3B, C, right panels) clearly showed the outline of the EC 
Table 2. Augmentation of endothelial cell cytotoxicity by recom- 
binant human tumor necrosis factor (TNF). 
% viability 
Toxin dose 
(CDso/ml)* No TNF TNF 
107 
105 
103 
10' 
0 
56.7 
85.6 
97.7 
105.0 
37.4 
60.4 
81.4 
90.3 
92.1 
NOTE. Confluent endothelial cells were incubated in triplicate for 48 h with 
the indicated doses of Shiga toxin in presence or absence of rhTNFa. The number 
of substratum-adherent cells was determined as described in Materials and Meth- 
ods. Data represent mean values of three separate xperiments. 
* Number of Vero cell CDso/ml. 
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Figure 3. Comparative analysis of Shiga toxin and Shiga-like toxin type II (SLT-II) binding to intact cells. Equivalent numbers of Vero 
cells, HeLa cells, and endothelial cells (EC) were treated with 109 Vero cell 50% cytotoxic doses of crude toxin preparations at 40C in the 
presence of NaN3. Bound toxins were detected with anti-toxin monoclonal antibodies and fluorescein-conjugated secondary antibody. The 
cells were outlined by simultaneous staining with a nonspecific fluorescent membrane probe. Fluorescence was measured using a Meridian 
ACAS 470 laser scanner in which fluorescence intensity was converted to the 15 color scale at right. Moving up the scale, colors represent 
increasing fluorescence intensity. A, Vero and HeLa cells (left and right panels, respectively) treated with Shiga toxin. B, EC treated with 
Shiga toxin (left) and membrane probe (right). C, EC treated with SLT-II (left) and membrane probe (right). D, EC treated with Escherichia 
coli DH5a concentrated sonicated lysate, (left) and membrane probe (right). 
present in the fields. As a control, concentrated sonicated 
lysates were prepared from E. coli DH5a in a manner analo- 
gous to that used to concentrate Shiga toxin (see Materials 
and Methods). The control lysates showed no binding to EC 
(figure 3D, left). In addition, the deletion of primary or sec- 
ondary antibody from the assay showed that nonspecific 
background fluorescence was very low in this procedure 
(data not shown). Therefore, the fluorescence detectable in 
Shiga toxin-treated cells is specifically due to toxin binding. 
These data suggest that one reason EC are less sensitive than 
Vero or HeLa cells to the cytotoxic effect of Shiga toxin may 
be low levels of toxin binding to the cells. 
Comparative quantitative analysis of toxin-specific glyco- 
lipid receptors in EC. Toxin-binding glycolipids present in 
Vero and HeLa cells and EC were detected by the direct 
binding of saturating amounts of Shiga toxin to thin-layer 
chromatograms of serial dilutions of membrane total glyco- 
lipid extracts (figure 4, lanes 6-15). Glycolipid standards 
were used to compare the glycolipids present in each cell line 
(figure 4, lanes 1-5, 16). In contrast to Vero and HeLa cells, 
the amount of toxin-binding glycolipids detected in EC 
membrane extracts prepared from equivalent cell wet 
weights was greatly reduced. Bound toxin was detected with 
Shiga toxin-specific MAb and 125I-labeled goat anti-mouse 
IgG antibody. Since the amount of toxin-specific glycolipids 
present in membrane extracts was previously shown to corre- 
late directly with the amount of bound toxin [45], we quanti- 
tated the relative amounts of toxin-binding glycolipids by 
direct densitometric scanning of the autoradiographs. HU- 
VEC and HSVEC contained 0.06 and 0.03 nM Gb3/mg of 
cells, respectively. In contrast, Vero and HeLa cells con- 
tained 80 and 25 nM Gb3/mg of cells, respectively. Thus, the 
diminished toxin-binding glycolipid content of EC com- 
pared with Vero and HeLa cells directly correlated with re- 
duced Shiga toxin sensitivity and toxin binding. 
Discussion 
The experiments reported here were designed to examine 
the role of crude or purified Shiga toxin, SLT-II, LPS, and 
recombinant cytokines in killing confluent human vascular 
endothelial cells and to compare the EC cytotoxicity with 
that of other cell lines. The incubation of EC with purified 
Shiga toxin resulted in a reduction in the numbers of viable 
cells remaining attached to gelatin-coated dishes, and this 
activity was neutralized by anti-Shiga toxin MAb, suggesting 
that Shiga toxin was the primary mediator of cytotoxicity in 
vitro. These results support and extend the findings of Obrig 
et al. [18], who demonstrated that rabbit polyclonal anti- 
Shiga toxin antibodies, as well as heat denaturation, totally 
neutralize the EC cytotoxic potential of Shiga toxin prepara- 
tions. These investigators also showed, however, that Shiga 
toxin, to a dose of 10-7 M, had a delayed (>48 h) cytotoxic 
effect on confluent HUVEC [18]. In contrast to their studies, 
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Figure 4. Quantitation of toxin- 
specific glycolipid receptor in hu- 
man saphenous vein endothelial 
cells (HSVEC), human umbilical 
vein endothelial cells (HUVEC), 
Vero cells, and HeLa cells. Shiga 
toxin was bound to glycolipids sep- 
arated by thin-layer chromatogra- 
phy, detected with anti-Shiga 
toxin monoclonal antibody and 
'25I-labeled goat anti-mouse IgG 
antibody, and visualized by autora- 
diography. By lane: 1-5, 100, 50, 
10, 5, and 1 ng globotriaosylcera- 
mide (Gb3), respectively; 6, 7, gly- 
colipids from I and 3 mg of Vero 
cells, respectively; 8, 9, glycolipids 
from 1 and 3 mg of HeLa cells, re- 
spectively; 10-12, glycolipids from 
1, 3, and 10 mg of HSVEC, respec- 
tively; 13-15, glycolipids from 1, 
3, and 10 mg of HUVEC, respec- 
tively; 16, 1 gg each of standard gly- 
colipids lactosylceramide (CDH), 
Gb3, and globotetraosylceramide 
(Gb4). All cell masses are ex- 
pressed according to wet weight. 
we detected a more rapid loss of EC viability, occurring 
within the first 24 h of incubation with toxin. These differ- 
ences in kinetics may be due to differences in the metabolic 
activity of the EC used in the cytotoxicity assays. Obrig et al. 
[18] cultured different concentrations of HUVEC at 370C 
for 12-24 h, and these cells were termed confluent or non- 
confluent. We seeded EC, monitored growth using an in- 
verted-phase microscope, and allowed the cells to replicate 
to a confluent state over 3-5 days. Since Shiga toxin acts by 
inhibiting protein synthesis, differences in target cell meta- 
bolic activity may have drastic effects on Shiga toxin sensi- 
tivity. 
The amount of toxin added to EC was based on the cyto- 
toxicity of the toxin preparations for Vero cells, a cell line 
that has been used to characterize toxin activity and toxin-re- 
ceptor interaction [7]. While EC are susceptible to Shiga 
toxin, they are at least 106-fold less sensitive than Vero cells. 
On the basis of the cytotoxic potential of Shiga toxin for Vero 
cells (1 CD50 - 1 pg of toxin), we estimate that 1 EC CD50 is 
- 1.4 X 10-8 M or ~ 10 gg of toxin. As previously reported 
for other cytotoxicity assays using Shiga toxin and SLTs [46, 
47], we noted a shallow dose response curve, that is, incuba- 
tion of EC with concentrations of Shiga toxin that differ 100- 
fold produced only slight changes in percentages of viability 
(compare 109 vs. 10' CD50, figure 1). In addition, we isolated 
viable EC, even when the cells were incubated with - 10 EC 
CD50 of Shiga toxin. Although previous studies have clearly 
demonstrated differential cytotoxicity between confluent 
and nonconfluent HUVEC [18], our data suggest that even 
within a population of confluent EC, there may be heteroge- 
neity in terms of susceptibility to Shiga toxin. 
Several lines of evidence suggest that endotoxins may con- 
tribute to the development of HUS. Bertani et al. [41] dem- 
onstrated that when rabbits were infused with E. coli 
0111:B4 LPS, marked damage to glomerular EC became 
apparent within 5 min. Changes in EC morphology preceded 
polymorphonuclear cell infiltration and fibrin deposition. 
These changes were consistent with those seen in the kidneys 
of HUS patients [16]. Barrett et al. [48] showed that a single 
sublethal dose of endotoxin given to rabbits 3 days after the 
initiation of continuous SLT-II infusion enhances the lethal 
effect of the toxin. In the in vitro cytotoxicity assays reported 
here, however, purified LPS derived from S. dysenteriae type 
1 or EHEC strains was not directly cytotoxic for EC at doses 
as high as 10 Ag/ml. This finding is in accordance with earlier 
studies showing that HUVEC are refractory to both LPS-me- 
diated direct cytotoxicity and changes in EC function at 
doses as high as 100 ,g/ml [49, 50]. In addition, we have 
shown that the addition of anti-Shiga toxin MAb to crude 
toxin preparations neutralizes cytotoxicity, and the coincu- 
bation of EC with LPS and purified Shiga toxin neither en- 
hanced nor inhibited EC cytotoxicity. However, the correla- 
tion of our in vitro cytotoxicity data with animal models of 
HUS should be made with caution. The capacity of endotox- 
ins to mediate alterations in cellular functions, particularly 
through the elicitation of endogenous cytokines, is now well 
documented [42, 51]. Thus, the contributory effect of endo- 
toxins in HUS may be mediated through changes in EC or 
inflammatory cell functions that have yet to be fully eluci- 
dated. 
Our data suggest that in the presence of the cytokine 
TNFa, the Shiga toxin EC CD50 may be reduced from 
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~ lO"8 M to as low as ~ lO"10 M (table 2). Although free 
Shiga toxin or SLTs in human sera have not been quanti- 
tated, it is not unreasonable to speculate that this lower dose 
of toxin may be in the physiologically relevant range [52]. In 
addition, Shiga toxin may exacerbate any cytotoxic effects 
mediated directly by cytokines. rhTNFa at 20 ng/ml or re- 
combinant human interleukin-10 at 100 pg/ml have been 
demonstrated not to be directly cytotoxic for HUVEC [53]. 
However, in the presence of the protein synthesis inhibitor 
cycloheximide or the RNA synthesis inhibitor actinomycin 
D, HUVEC have been shown to be sensitized to the cyto- 
toxic effects of these cytokines [53]. Therefore, by inhibiting 
de novo protein synthesis, Shiga toxin and SLTs may act to 
block the protective mechanism(s) necessary to overcome 
cytokine-mediated direct cytotoxicity. 
We used an indirect immunofluorescence assay to moni- 
tor the binding of Shiga toxin to EC. Toxin-specific binding 
to EC was reduced relative to Vero and HeLa cells. We also 
noted cell-to-cell variations in toxin binding when Vero or 
HeLa cells or EC were treated with equivalent doses of Shiga 
toxin. Again, this suggests that the cells may consist of hetero- 
geneous populations in terms of the capacity to bind Shiga 
toxin. Toxin binding studies using Shiga toxin-sensitive and 
resistant HeLa cell lines have shown that 10-fold differences 
in toxin binding sites can produce 109 -fold variability in 
toxin sensitivity [46, 47]. Thus, the minute differences in 
fluorescence we observed among cells in the toxin binding 
experiments may represent profound differences in Shiga 
toxin sensitivity. To more directly compare differences in 
toxin binding, we examined the glycolipid components of 
the cell membranes. Both EC types contained ~ 1000-fold 
less Gb3 than did Vero cells. Thus, the relative insensitivity 
of human EC derived from large veins may be directly corre- 
lated with reduced numbers of toxin-specific membrane re- 
ceptors, and our data support earlier studies showing a corre- 
lation of Shiga toxin sensitivity with membrane Gb3 content 
[45, 47, 54]. 
Our data demonstrating the relative insensitivity of human 
vascular EC to Shiga toxin and the paucity of toxin-specific 
membrane receptors suggest that the use of these cells may 
not represent the most appropriate in vitro model of HUS. 
Histopathologic studies have shown, however, that glomeru- 
lar EC damage is a hallmark of HUS [16, 41]. Boyd and 
Lingwood [45] showed that Gb3 is the predominant neutral 
glycolipid in human renal tissue; their values were ~2- to 
30-fold greater than the amount of Gb3 we detected in EC. 
Although the amount of glycolipid in a complex tissue sam- 
ple may not accurately reflect the relative amount in a partic- 
ular cell type, the data suggest that EC derived from large 
veins may differ in their toxin-receptor content from glomer- 
ular endothelial cells. Finally, it is important to note that 
human vascular EC and glomerular EC are functionally and 
morphologically distinct cells. Glomerular EC are highly 
fenestrated and coated with a sialoglycoprotein-rich anionic 
glycocalix [55]. The structural and functional differences in 
EC may include differential responses to Shiga toxin or LPS. 
There is one report that endotoxins are directly cytotoxic for 
human glomerular endothelial cells [56]. Further studies on 
the effect of Shiga toxin and endotoxin on human glomeru- 
lar cells are clearly warranted and are currently in progress in 
our laboratory. 
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